Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs SAR 440340 (Primary) ; Corticosteroids
  • Indications Chronic obstructive pulmonary disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 30 Jan 2019 Planned End Date changed from 23 Apr 2020 to 1 Apr 2020.
    • 30 Jan 2019 Planned primary completion date changed from 6 Dec 2019 to 1 Dec 2019.
    • 21 Jan 2019 Planned primary completion date changed from 23 Apr 2020 to 6 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top